Arrowhead Pharmaceuticals Inc. (ARWR)

29.95
NASDAQ : Health Technology
Prev Close 30.14
Day Low/High 29.61 / 30.46
52 Wk Low/High 10.41 / 36.80
Avg Volume 1.40M
Exchange NASDAQ
Shares Outstanding 95.30M
Market Cap 2.87B
EPS -0.70
P/E Ratio 62.39
Div & Yield N.A. (N.A)
First Week of December 16th Options Trading For Arrowhead Pharmaceuticals (ARWR)

First Week of December 16th Options Trading For Arrowhead Pharmaceuticals (ARWR)

Investors in Arrowhead Pharmaceuticals Inc saw new options become available this week, for the December 16th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Arrowhead Pharmaceuticals Presents Preclinical Data On Renal Cell Carcinoma Program At AACR 2016

Arrowhead Pharmaceuticals Presents Preclinical Data On Renal Cell Carcinoma Program At AACR 2016

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented a poster on ARC-HIF2, its preclinical development program targeting HIF2-a for the treatment of renal cell carcinoma (RCC), at the American Association for...

Here’s Why Arrowhead Pharma (ARWR) Stock Closed Up Today

Here’s Why Arrowhead Pharma (ARWR) Stock Closed Up Today

Arrowhead Pharma (ARWR) stock continued to climb on Thursday after the release of ‘promising’ data about its lead product candidate for the treatment of the hepatitis B infection yesterday.

Arrowhead Pharma (ARWR) Stock Spikes on Promising Hepatitis B Data

Arrowhead Pharma (ARWR) Stock Spikes on Promising Hepatitis B Data

Arrowhead Pharma (ARWR) stock are rising following the release of encouraging data about the company's lead product candidate for the treatment of the hepatitis B virus infection.

Arrowhead Pharmaceuticals Presents Promising ARC-520 Hepatitis B Data At The International Liver Congress™ 2016

Arrowhead Pharmaceuticals Presents Promising ARC-520 Hepatitis B Data At The International Liver Congress™ 2016

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that three presentations are being made on ARC-520, its investigational medicine for the treatment of chronic hepatitis B infection, at The International Liver...

Arrowhead Research Changes Name To Arrowhead Pharmaceuticals

Arrowhead Research Changes Name To Arrowhead Pharmaceuticals

Arrowhead Research Corporation (NASDAQ:ARWR) today announced that it has changed its corporate name to Arrowhead Pharmaceuticals, Inc.

Arrowhead To Present At Upcoming April Conferences

Arrowhead To Present At Upcoming April Conferences

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that the company will make presentations at the following upcoming events.

Arrowhead Presents Promising New Preclinical Data On ARC-F12 At AAAAI 2016

Arrowhead Presents Promising New Preclinical Data On ARC-F12 At AAAAI 2016

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today presented additional preclinical data suggesting that ARC-F12, an RNAi therapeutic that inhibits the...

Arrowhead To Present At Upcoming March Conferences

Arrowhead To Present At Upcoming March Conferences

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that the company will make presentations at the following upcoming events.

Arrowhead Research (ARWR) Weak On High Volume Today

Arrowhead Research (ARWR) Weak On High Volume Today

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a weak on high relative volume candidate

Arrowhead To Present At Upcoming February Conferences

Arrowhead To Present At Upcoming February Conferences

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that the company will make presentations at the following upcoming events.

Arrowhead Reports Fiscal 2016 First Quarter Results

Arrowhead Reports Fiscal 2016 First Quarter Results

Arrowhead Research Corporation (NASDAQ: ARWR) today announced financial results for its fiscal 2016 first quarter ended December 31, 2015.

Arrowhead Research (ARWR) Is Strong On High Volume Today

Arrowhead Research (ARWR) Is Strong On High Volume Today

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a strong on high relative volume candidate

Arrowhead To Webcast Fiscal 2016 First Quarter Results

Arrowhead To Webcast Fiscal 2016 First Quarter Results

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will host a webcast and conference call on Tuesday, February 9, 2015, at 4:30 p.

Arrowhead's ARC-AAT Granted EMA Orphan Drug Designation

Arrowhead's ARC-AAT Granted EMA Orphan Drug Designation

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that the European Medicines Agency (EMA) granted Orphan Drug Designation to ARC-AAT for...

Arrowhead Begins Dosing The Phase 2b MONARCH Combination Study Of ARC-520 In Patients With Chronic Hepatitis B Infection

Arrowhead Begins Dosing The Phase 2b MONARCH Combination Study Of ARC-520 In Patients With Chronic Hepatitis B Infection

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, dosed the first patient in the Phase 2b MONARCH combination study of ARC-520, it's RNAi-based drug for the...

5 Stocks Ready for Breakouts

5 Stocks Ready for Breakouts

These stocks look ready to break out and trade higher from current levels.

Arrowhead Reports Fiscal 2015 Year End Results

Arrowhead Reports Fiscal 2015 Year End Results

Arrowhead Research Corporation (NASDAQ: ARWR) today announced financial results for its fiscal 2015 fourth quarter and year ended September 30, 2015.

Arrowhead Added To NASDAQ Biotechnology Index®

Arrowhead Added To NASDAQ Biotechnology Index®

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ: NBI) as...

5 Stocks Set to Soar on Bullish Earnings

5 Stocks Set to Soar on Bullish Earnings

These heavily shorted stocks could get squeezed much higher if they report positive earnings this week.

Arrowhead To Webcast Fiscal 2015 Year End Results

Arrowhead To Webcast Fiscal 2015 Year End Results

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will host a webcast and conference call to discuss its financial results for the...

Strong On High Relative Volume: Arrowhead Research (ARWR)

Strong On High Relative Volume: Arrowhead Research (ARWR)

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a strong on high relative volume candidate

Arrowhead's ARC-520 Leads To Consistent Immune Reactivation In Chimpanzees With Chronic Hepatitis B Infection

Arrowhead's ARC-520 Leads To Consistent Immune Reactivation In Chimpanzees With Chronic Hepatitis B Infection

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, presented data at HEP DART 2015 showing that in chronically HBV-infected chimpanzees treated with ARC-520 in...

Arrowhead Research (ARWR) Stock Rises on Clinical Trial Results

Arrowhead Research (ARWR) Stock Rises on Clinical Trial Results

Arrowhead Research (ARWR) stock is rising on Monday, after the company announced that its Hepatitis B treatment could produce 'deep and durable reductions' of the disease's antigens and DNA.

January 2018 Options Now Available For Arrowhead Research (ARWR)

January 2018 Options Now Available For Arrowhead Research (ARWR)

Investors in Arrowhead Research Corp saw new options begin trading today, for the January 2018 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 795 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Arrowhead Late-Breaking Clinical Data Shows That ARC-520 Can Produce Deep And Durable Reductions Of Hepatitis B Viral Antigens And DNA

Arrowhead Late-Breaking Clinical Data Shows That ARC-520 Can Produce Deep And Durable Reductions Of Hepatitis B Viral Antigens And DNA

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, presented data from a Phase 2a clinical study at The AASLD Liver Meeting 2015 ® demonstrating that...

Arrowhead Presents Data Showing Robust Sustained Anti-viral Effects With ARC-520 In Hepatitis B Infected Chimpanzees

Arrowhead Presents Data Showing Robust Sustained Anti-viral Effects With ARC-520 In Hepatitis B Infected Chimpanzees

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, presents data at the AASLD Liver Meeting 2015 ® in an oral presentation and a poster showing that...

Arrowhead To Present At Upcoming Conferences

Arrowhead To Present At Upcoming Conferences

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that the company will make presentations at the following upcoming events.

First Week Of June 2016 Options Trading For Arrowhead Research (ARWR)

First Week Of June 2016 Options Trading For Arrowhead Research (ARWR)

Investors in Arrowhead Research Corp saw new options begin trading this week, for the June 2016 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Arrowhead Late-Breaker Abstract Accepted For Presentation At The AASLD Liver Meeting 2015

Arrowhead Late-Breaker Abstract Accepted For Presentation At The AASLD Liver Meeting 2015

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that additional clinical data on ARC-520, its RNAi therapeutic candidate for the treatment of...

TheStreet Quant Rating: C+ (Hold)